Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Go back to Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
(NASDAQ: KZIA) Delayed: 13.80 -0.06 (0.43%)
Previous Close $13.86    52 Week High
Open $13.91    52 Week Low
Day High $14.28    P/E N/A 
Day Low $13.50    EPS
Volume 33,726